Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

An observational analysis finds the drugs may lower the risk of substance abuse and cognitive issues. But the findings need ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are brand-name solutions for subcutaneous injection. Doctors prescribe them to help manage blood sugar levels in people with type 2 diabetes. This ...

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations have increased by an average 98% since they hit the market, according to ...

These drugs are the GLP1 receptor agonists like Exenatide, Liraglutde, Dulaglutide, Semaglutide and the dual GLP/ GIP Analogue Tirzepatide. Both these drugs are recent innovations that have taken ...

Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond ...